Contact
Please use this form to send email to PR contact of this press release:
Axovant Announces Dosing of First Patient in Clinical Program for AXO-AAV-GM1, a Novel Gene Therapy for GM1 Gangliosidosis
TO:
Please use this form to send email to PR contact of this press release:
Axovant Announces Dosing of First Patient in Clinical Program for AXO-AAV-GM1, a Novel Gene Therapy for GM1 Gangliosidosis
TO: